{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:49:54Z","timestamp":1786549794132,"version":"build-2736575974"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,8,1]]},"abstract":"<jats:sec id=\"ab-hoi260031-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>The optimal duration of dual antiplatelet therapy (DAPT) in patients at high bleeding risk (HBR) undergoing percutaneous coronary intervention (PCI) remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-5\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To evaluate the safety and efficacy of abbreviated DAPT durations in patients at HBR undergoing PCI.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-6\">\n                    <jats:title>Data Sources<\/jats:title>\n                    <jats:p>PubMed, Embase, and Cochrane Central Register of Controlled Trials were searched from inception to October 26, 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-7\">\n                    <jats:title>Study Selection<\/jats:title>\n                    <jats:p>Randomized clinical trials (RCTs) comparing abbreviated (ie, 1- to 3-month) vs standard (ie, 6- to 12-month) DAPT durations in patients at HBR without an indication for oral anticoagulation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-8\">\n                    <jats:title>Data Extraction and Synthesis<\/jats:title>\n                    <jats:p>A pairwise meta-analysis was performed to compare abbreviated (ie, 1-month to 3-month) vs standard (ie, \u22656-month) DAPT durations. A frequentist network meta-analysis was performed to compare 1-month, 3-month, and standard DAPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-9\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>The coprimary safety and efficacy end points were major or clinically relevant nonmajor bleeding (MCRB) and major adverse cardiovascular events (MACE; ie, a composite of cardiovascular death, myocardial infarction, or stroke).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-10\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 14 RCTs encompassing 11\u202f398 patients at HBR (mean [range] age, 74.7 [68.6-80.0] years; 39.1% female and 60.9% male) were included. Compared with standard DAPT, abbreviated DAPT was associated with lower MCRB (risk ratio [RR], 0.71; 95% CI, 0.55-0.92;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.009) and major bleeding (RR, 0.76; 95% CI, 0.59-0.99;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04). The risks of MACE (RR, 0.97; 95% CI, 0.81-1.16;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.76) and its individual components did not differ between abbreviated and standard regimens. An increased risk of MACE was observed with 1-month vs 3-month DAPT in the single trial comparing these regimens, but the network estimate was nonsignificant (RR, 1.28; 95% CI, 0.96-1.72).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hoi260031-11\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>In this systematic review and meta-analysis, for patients at HBR undergoing PCI, abbreviated DAPT was associated with a lower risk of bleeding and, at least for 3-month regimens, was not associated with an increase in fatal or nonfatal ischemic cardiovascular or cerebrovascular events compared with standard 6- to 12-month DAPT.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.1922","type":"journal-article","created":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T15:32:11Z","timestamp":1782315131000},"page":"758","source":"Crossref","is-referenced-by-count":0,"title":["Dual Antiplatelet Therapy Duration in Patients at High Bleeding Risk"],"prefix":"10.1001","volume":"11","author":[{"given":"Andrea","family":"Zito","sequence":"first","affiliation":[{"name":"Department of Cardiovascular and Pulmonary Sciences, Catholic University of the Sacred Heart, Rome, Italy"},{"name":"Valve Center, Fondazione Poliambulanza Istituto Ospedaliero, Brescia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Landi","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deepak L.","family":"Bhatt","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shao-Liang","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"De Luca","sequence":"additional","affiliation":[{"name":"Department of Cardiology, AOU Policlinico G Martino, University of Messina, Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Franzone","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeon-Cheol","family":"Gwon","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeehoon","family":"Kang","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joo-Yong","family":"Hahn","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Jin","family":"Hong","sequence":"additional","affiliation":[{"name":"Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsoo","family":"Jang","sequence":"additional","affiliation":[{"name":"Division of Cardiology, CHA Gangnam Medical Center, CHA University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byeong-Keuk","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Severance Cardiovascular Hospital, Yonsei University College of Medicine, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyo-Soo","family":"Kim","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Kimura","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Hirakata Kohsai Hospital, Hirakata, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York"},{"name":"Associate editor, JAMA Cardiology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Woo","family":"Park","sequence":"additional","affiliation":[{"name":"Cardiovascular Center, Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe Gabriel","family":"Steg","sequence":"additional","affiliation":[{"name":"Universit\u00e9 Paris-Cit\u00e9, Assistance Publique-H\u00f4pitaux de Paris, H\u00f4pital Bichat, French Alliance for Cardiovascular Trials, INSERM-U1148, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregg W.","family":"Stone","sequence":"additional","affiliation":[{"name":"Mount Sinai Fuster Heart Hospital, Icahn School of Medicine at Mount Sinai, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Vranckx","sequence":"additional","affiliation":[{"name":"Department of Cardiology and Critical Care Medicine, Jessa Ziekenhuis, Hasselt, Belgium"},{"name":"Faculty of Medicine and Life Sciences, University of Hasselt, Hasselt, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Windecker","sequence":"additional","affiliation":[{"name":"Associate editor, JAMA Cardiology"},{"name":"Department of Cardiology, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Valgimigli","sequence":"additional","affiliation":[{"name":"Cardiocentro Ticino Institute, Ente Ospedaliero Cantonale (EOC), Lugano, Switzerland"},{"name":"Faculty of Biomedical Sciences, University of Italian Switzerland, Lugano, Switzerland"},{"name":"Faculty of Medicine, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"3","key":"hoi260031r1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1093\/eurheartj\/ehx419","article-title":"2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS).","volume":"39","author":"Valgimigli","year":"2018","journal-title":"Eur Heart J"},{"issue":"15","key":"hoi260031r2","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1093\/eurheartj\/ehr204","article-title":"Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology.","volume":"32","author":"Steg","year":"2011","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi260031r3","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1056\/NEJMra1607714","article-title":"Management of antithrombotic therapy after acute coronary syndromes.","volume":"384","author":"Rodriguez","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"hoi260031r4","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1161\/CIRCULATIONAHA.119.040167","article-title":"Defining high bleeding risk in patients undergoing percutaneous coronary intervention.","volume":"140","author":"Urban","year":"2019","journal-title":"Circulation"},{"issue":"1332","key":"hoi260031r5","doi-asserted-by":"publisher","first-page":"n1332","DOI":"10.1136\/bmj.n1332","article-title":"P2Y12 inhibitor monotherapy or dual antiplatelet therapy after coronary revascularisation: individual patient level meta-analysis of randomised controlled trials.","volume":"373","author":"Valgimigli","year":"2021","journal-title":"BMJ"},{"issue":"10456","key":"hoi260031r6","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1016\/S0140-6736(24)01616-7","article-title":"De-escalation to ticagrelor monotherapy versus 12 months of dual antiplatelet therapy in patients with and without acute coronary syndromes: a systematic review and individual patient-level meta-analysis of randomised trials.","volume":"404","author":"Valgimigli","year":"2024","journal-title":"Lancet"},{"issue":"10516","key":"hoi260031r7","doi-asserted-by":"publisher","first-page":"2244","DOI":"10.1016\/S0140-6736(25)01571-5","article-title":"Dual antiplatelet therapy after percutaneous coronary intervention according to bleeding risk (HOST-BR): an open-label, multicentre, randomised clinical trial.","volume":"406","author":"Kang","year":"2025","journal-title":"Lancet"},{"key":"hoi260031r8","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"issue":"11","key":"hoi260031r9","doi-asserted-by":"publisher","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations.","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"issue":"10073","key":"hoi260031r10","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1016\/S0140-6736(17)30397-5","article-title":"Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials.","volume":"389","author":"Costa","year":"2017","journal-title":"Lancet"},{"issue":"36","key":"hoi260031r11","doi-asserted-by":"publisher","first-page":"3415","DOI":"10.1093\/eurheartj\/ehae177","article-title":"2024 ESC Guidelines for the management of chronic coronary syndromes.","volume":"45","author":"Vrints","year":"2024","journal-title":"Eur Heart J"},{"issue":"38","key":"hoi260031r12","doi-asserted-by":"publisher","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the management of acute coronary syndromes.","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur Heart J"},{"issue":"9","key":"hoi260031r13","doi-asserted-by":"publisher","first-page":"e9","DOI":"10.1161\/CIR.0000000000001168","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA Guideline for the management of patients with chronic coronary disease: a report of the American Heart Association\/American College of Cardiology Joint Committee on Clinical Practice Guidelines.","volume":"148","author":"Virani","year":"2023","journal-title":"Circulation"},{"issue":"6","key":"hoi260031r14","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/CIRCULATIONAHA.124.072009","article-title":"Derivation and validation of the PRECISE-HBR score to predict bleeding after percutaneous coronary intervention.","volume":"151","author":"Gragnano","year":"2025","journal-title":"Circulation"},{"issue":"8","key":"hoi260031r15","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1161\/CIRCULATIONAHA.123.066943","article-title":"Stopping aspirin within 1 month after stenting for ticagrelor monotherapy in acute coronary syndrome: the T-PASS randomized noninferiority trial.","volume":"149","author":"Hong","year":"2024","journal-title":"Circulation"},{"issue":"10439","key":"hoi260031r16","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/S0140-6736(24)00473-2","article-title":"Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial.","volume":"403","author":"Ge","year":"2024","journal-title":"Lancet"},{"issue":"10151","key":"hoi260031r17","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1016\/S0140-6736(18)31858-0","article-title":"Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial.","volume":"392","author":"Vranckx","year":"2018","journal-title":"Lancet"},{"issue":"18","key":"hoi260031r18","doi-asserted-by":"publisher","first-page":"2223","DOI":"10.1016\/j.jacc.2019.08.1038","article-title":"Ticagrelor alone versus dual antiplatelet therapy from 1 month after drug-eluting coronary stenting.","volume":"74","author":"Franzone","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"21","key":"hoi260031r20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1056\/NEJMoa1908419","article-title":"Ticagrelor with or without aspirin in high-risk patients after PCI.","volume":"381","author":"Mehran","year":"2019","journal-title":"N Engl J Med"},{"issue":"25","key":"hoi260031r21","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1161\/CIRCULATIONAHA.123.064473","article-title":"Defining strategies of modulation of antiplatelet therapy in patients with coronary artery disease: a consensus document from the academic research consortium.","volume":"147","author":"Capodanno","year":"2023","journal-title":"Circulation"},{"issue":"7","key":"hoi260031r22","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jacc.2018.11.048","article-title":"Dual antiplatelet therapy duration based on ischemic and bleeding risks after coronary stenting.","volume":"73","author":"Costa","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"7","key":"hoi260031r23","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1016\/j.jacc.2025.05.010","article-title":"Recurrent events analysis of MASTER DAPT: total ischemic and bleeding events after abbreviated vs prolonged DAPT in HBR patients.","volume":"86","author":"Bongiovanni","year":"2025","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"hoi260031r24","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1093\/eurheartj\/ehac706","article-title":"Dual antiplatelet therapy duration after percutaneous coronary intervention in high bleeding risk: a meta-analysis of randomized trials.","volume":"44","author":"Costa","year":"2023","journal-title":"Eur Heart J"},{"issue":"5","key":"hoi260031r25","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1001\/jamacardio.2024.0133","article-title":"Ticagrelor or clopidogrel monotherapy vs dual antiplatelet therapy after percutaneous coronary intervention: a systematic review and patient-level meta-analysis.","volume":"9","author":"Valgimigli","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"2","key":"hoi260031r26","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jacc.2023.04.051","article-title":"P2Y12 inhibitor or aspirin monotherapy for secondary prevention of coronary events.","volume":"82","author":"Gragnano","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"10508","key":"hoi260031r27","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S0140-6736(25)01562-4","article-title":"Clopidogrel versus aspirin for secondary prevention of coronary artery disease: a systematic review and individual patient data meta-analysis.","volume":"406","author":"Valgimigli","year":"2025","journal-title":"Lancet"},{"issue":"3","key":"hoi260031r28","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/nrcardio.2017.206","article-title":"Current and future antiplatelet therapies: emphasis on preserving haemostasis.","volume":"15","author":"McFadyen","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"15","key":"hoi260031r29","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1016\/j.jacc.2012.06.043","article-title":"A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).","volume":"60","author":"Kim","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"23","key":"hoi260031r30","doi-asserted-by":"publisher","first-page":"2510","DOI":"10.1001\/jama.2013.282183","article-title":"Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial.","volume":"310","author":"Feres","year":"2013","journal-title":"JAMA"},{"issue":"11","key":"hoi260031r31","doi-asserted-by":"publisher","first-page":"e990","DOI":"10.4244\/EIJ-D-19-00539","article-title":"Final results of the randomised evaluation of short-term dual antiplatelet therapy in patients with acute coronary syndrome treated with a new-generation stent (REDUCE trial).","volume":"15","author":"De Luca","year":"2019","journal-title":"EuroIntervention"},{"issue":"24","key":"hoi260031r32","doi-asserted-by":"publisher","first-page":"2428","DOI":"10.1001\/jama.2019.8146","article-title":"Effect of P2Y12 inhibitor monotherapy vs dual antiplatelet therapy on cardiovascular events in patients undergoing percutaneous coronary intervention: the SMART-CHOICE randomized clinical trial.","volume":"321","author":"Hahn","year":"2019","journal-title":"JAMA"},{"issue":"24","key":"hoi260031r33","doi-asserted-by":"publisher","first-page":"2414","DOI":"10.1001\/jama.2019.8145","article-title":"Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial.","volume":"321","author":"Watanabe","year":"2019","journal-title":"JAMA"},{"issue":"23","key":"hoi260031r34","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1001\/jama.2020.7580","article-title":"Effect of ticagrelor monotherapy vs ticagrelor with aspirin on major bleeding and cardiovascular events in patients with acute coronary syndrome: the TICO randomized clinical trial.","volume":"323","author":"Kim","year":"2020","journal-title":"JAMA"},{"issue":"16","key":"hoi260031r35","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/j.jcin.2021.06.003","article-title":"1-Month dual-antiplatelet therapy followed by aspirin monotherapy after polymer-free drug-coated stent implantation: one-month DAPT trial.","volume":"14","author":"Hong","year":"2021","journal-title":"JACC Cardiovasc Interv"},{"issue":"18","key":"hoi260031r36","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1056\/NEJMoa2108749","article-title":"Dual antiplatelet therapy after PCI in patients at high bleeding risk.","volume":"385","author":"Valgimigli","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"hoi260031r37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamacardio.2021.5244","article-title":"Comparison of clopidogrel monotherapy after 1 to 2 months of dual antiplatelet therapy with 12 months of dual antiplatelet therapy in patients with acute coronary syndrome: the STOPDAPT-2 ACS randomized clinical trial.","volume":"7","author":"Watanabe","year":"2022","journal-title":"JAMA Cardiol"},{"issue":"19","key":"hoi260031r38","doi-asserted-by":"publisher","first-page":"2224","DOI":"10.1016\/j.jacc.2016.02.064","article-title":"Coronary thrombosis and major bleeding after PCI with drug-eluting stents: risk scores from PARIS.","volume":"67","author":"Baber","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"hoi260031r39","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1161\/CIRCOUTCOMES.111.000072","article-title":"Perceived risk of ischemic and bleeding events in acute coronary syndromes.","volume":"6","author":"Chew","year":"2013","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"hoi260031r40","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-20-01197","article-title":"Mortality after bleeding versus myocardial infarction in coronary artery disease: a systematic review and meta-analysis.","author":"Piccolo","journal-title":"EuroIntervention"},{"issue":"11","key":"hoi260031r41","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1093\/eurheartj\/ehw525","article-title":"Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial.","volume":"38","author":"Valgimigli","year":"2017","journal-title":"Eur Heart J"},{"key":"hoi260031r19","unstructured":"IqWIG. General methods. Accessed May 26, 2026. https:\/\/www.iqwig.de\/methoden\/general-methods_version-7-0.pdf"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2850862\/jamacardiology_zito_2026_oi_260031_1786123769.97391.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T15:00:44Z","timestamp":1786546844000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2850862"}},"subtitle":["A Systematic Review and Meta-Analysis"],"short-title":[],"issued":{"date-parts":[[2026,8,1]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.1922","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,1]]}}}